Skip to main content

Clinical Trials Using Capecitabine

Review the clinical trials studying capecitabine on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 51-75 of 87

Atezolizumab with Capecitabine and Oxaliplatin Before Surgery for the Treatment of Resectable Non-Metastatic Proficient Mismatch Repair Colon Cancer, NICER Trial
Status: Active
Location: 2 locations
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
Status: Active
Location: 2 locations
Sarilumab plus Capecitabine for the Treatment of HER2 Negative Metastatic Breast Cancer and Stage I-III Triple Negative Breast Cancer with High-Risk Residual Disease, the EMPOWER Trial
Status: Active
Location: 2 locations
Zunsemetinib in Combination with Capecitabine for the Treatment of Patients with Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer
Status: Active
Location: 2 locations
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
Status: Active
Location: 3 locations
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Status: Active
Location: 2 locations
No Surgery Trial / Two Dose-escalation Strategies
Status: Active
Location: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
Low Dose Capecitabine for the Treatment of Locally Advanced and Metastatic HER2 Negative Breast Cancer
Status: Active
Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Adaptive Therapy with Capecitabine for the Treatment of Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer
Status: Active
Location: Mayo Clinic in Arizona, Scottsdale, Arizona
Hypofractionated Stereotactic Body Radiation Therapy and Fluorouracil or Capecitabine with or without Zoledronic Acid in Treating Patients with Locally Advanced Pancreatic Cancer
Status: Active
Location: University of Nebraska Medical Center, Omaha, Nebraska
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Capecitabine or Trastuzumab Emtansine with Radiation Therapy for the Treatment of High-Risk Stage I-IIIB Breast Cancer
Status: Active
Location: University of Virginia Cancer Center, Charlottesville, Virginia
FOLFOX, Botensilimab, and Balstilimab for the Treatment of Microsatellite Stable Localized Rectal Cancer before Surgery
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
A Vaccine (STEMVAC) with Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
ctDNA-Directed Chemotherapy after Hepatectomy for the Treatment of Colorectal Liver Metastases
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Chemotherapy with or without Radiation or Surgery in Treating Participants with Oligometastatic Esophageal or Gastric Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
A Sequential Treatment Plan for the Treatment of Hormone Positive Metastatic Breast Cancer
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Durvalumab in Combination with Chemotherapy in Treating Patients with Advanced Solid Tumors, DURVA+ Trial
Status: Active
Location: National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland
Capecitabine with or without Tetrathiomolybdate and Pembrolizumab for the Treatment of Triple Negative Breast Cancer at High Risk for Relapse
Status: Active
Location: Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon, New Hampshire
A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Chemotherapy with Radiation for the Treatment of Rectal Cancer
Status: Active
Location: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas